

S 4302

Biologics Market Transparency Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: May 25, 2022

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introdu

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709) (May 25, 2022)

Official Text: https://www.congress.gov/bill/117th-congress/senate-bill/4302

Sponsor

Name: Sen. Kaine, Tim [D-VA]

Party: Democratic • State: VA • Chamber: Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cassidy, Bill [R-LA]	R · LA		May 25, 2022
Sen. Hassan, Margaret Wood [D-NH]	D · NH		May 25, 2022
Sen. Marshall, Roger [R-KS]	R · KS		May 25, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 25, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 HR 7035	Related bill	Mar 10, 2022: Referred to the Subcommittee on Health.

Summary (as of May 25, 2022)

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

## Actions Timeline

---

- **May 25, 2022:** Introduced in Senate
- **May 25, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)